Join our daily newsletter At The Bell to receive exclusive market insights
Artrya Ltd (ASX:AYA) has seen its shares pop +40% on Thursday after the company secured fresh FDA approval that could unlock revenue pathways.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
That FDA approval relates to the company’s Salix “AI-powered cloud platform,” which has been billed as a real-time diagnostic product for coronary artery disease; that vague pivot to AI is probably less important to the market than the more traditional impact of an FDA approval in the first place.
Notably, the company reported on Thursday that the move expands ‘U.S. commercial opportunities’ given that Artrya could, assuming meaningful uptake of Salix, “charge fees per scan assessed.”
Because the company is pivoting to America, that could fetch them US$950 for each assessment in the U.S. medicare ecosystem.
So, in other words, the company’s got a fee machine.
As for what Salix does? It scans the body for “high-risk plaque,” an indicator of heart disease that, in Artrya’s words, can be easily missed. Here we are talking about plaque in the arteries and not in the dental sense (in case that needed clarification).
Of course, all this depends on uptake. To be fair, clearly, the market sees that as a given.
“Artrya’s go-to-market strategy for the U.S. is built around three strategic partnerships with mid-sized U.S. hospital systems,” the company explained Thursday.
“The first of these, Tanner Health, signed a commercial agreement… in July 2025, and the integration of Northeast Georgia Health and Cone Health is progressing and will be completed in coming months.”
The big takeaway, arguably, is that Artryas has just inked YTD returns of +235% after struggling to get back to 2021 levels.
AYA last traded at $1.78/sh.
Join the discussion: See what HotCopper users are saying about Artrya Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
